{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-067474","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.132367+00:00","generated_at":"2026-06-11T09:23:58.202441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Citius Q3 net loss $8.5M; FDA CRL for LYMPHIR (no safety/efficacy issues); $33.3M cash runway to Aug 2024","bullets":["Net loss of $8.5M ($0.06 EPS) for Q3 2023; nine-month loss $22.6M ($0.15 EPS).","Cash $33.3M, runway through Aug 2024; $13.8M net from May 2023 $1.20/share offering.","Mino-Lok Phase 3 trial achieved 92 required events (pending confirmation); Halo-Lido Phase 2b topline positive.","LYMPHIR received FDA CRL on July 28; no clinical safety/efficacy issues; planning resubmission.","R&D expenses $3.8M (down from $4.9M); G&A $3.7M (up from $3.0M) due to pre-launch activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-067474","json":"https://secwatch.observer/filing/0001213900-23-067474.json","markdown":"https://secwatch.observer/filing/0001213900-23-067474.md","text":"https://secwatch.observer/filing/0001213900-23-067474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/0001213900-23-067474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/ea183558-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:23:58.202441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df652692609894d05573174f66902540245843bc","claim":"Citius Pharmaceuticals, Inc. reported the fiscal third quarter ended June 30, 2023 results: net income Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023.","evidence_excerpt":"Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506251/000121390023067474/0001213900-23-067474-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal third quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}